We investigated the eect of cell transformation by v-src on the expression and tyrosine phosphorylation of SHPS-1, a putative docking protein for SHP-1 and SHP-2. We found that transformation by v-src virtually inhibited the SHPS-1 expression at mRNA level. While nontransforming Src kinases including c-Src, nonmyristoylated forms of v-Src had no inhibitory eect on SHPS-1 expression, transforming Src kinases including wild-type v-Src and chimeric mutant of c-Src bearing vSrc SH3 substantially suppressed the SHPS-1 expression. In cells expressing temperature sensitive mutant of v-Src, suppression of the SHPS-1 expression was temperature-dependent. In contrast, tyrosine phosphorylation of SHPS-1 was rather activated in cells expressing c-Src or nonmyristoylated forms of v-Src. SHPS-1 expression in SR3Y1 was restored by treatment with herbimycin A, a potent inhibitor of tyrosine kinase, or by the expression of dominant negative form of Ras. Contrary, active form of Mek1 markedly suppressed SHPS-1 expression. Finally, overexpression of SHPS-1 in SR3Y1 led to the drastic reduction of anchorage independent growth of the cells. Taken together, our results suggest that the suppression of SHPS-1 expression is a pivotal event for cell transformation by v-src, and the Ras-MAP kinase cascade plays a critical role in the suppression.
Introduction
Cell transformation by Rous sarcoma virus (RSV) is mediated by the v-Src kinase, a membrane-bound protein tyrosine kinase (Jove and Hanafusa, 1987) . The v-Src structure relevant to its transforming activity has been characterized well with a series of mutant src genes. While v-src is strongly transforming, its cellular counterpart, c-src, is inactive in transformation (Iba et al., 1984) . Point mutations in c-src that change the sequence to those of v-src render the protein highly oncogenic and active in kinase (Kato et al., 1986) . The N-terminal 14 amino acids are critical for myristoylation, membrane binding, and for transforming activity of v-Src Kamps et al., 1985) . The N-terminal part between the membrane-binding and the kinase domains contains the Src homology 3 (SH3) and the Src homology 2 (SH2) domains which is required for cell transformation (Cross et al., 1985) and regulates substrate recognition (Pawson, 1995) . By use of mutant src genes, several cellular proteins have been described as transformation-relevant substrates of v-Src kinase. These include; b-catenin (Hamaguchi et al., 1993a) ; glycoproteins of 95 kDa and 130 kDa (Hamaguchi et al., 1990; Kozuma et al., 1990) ; connexin-43 (Crow et al., 1992; Kanemitsu et al., 1997) ; 120-kDa protein (Linder and Burr, 1988) . Thus, mutant src genes have been utilized as an ecient tool to characterize substrate proteins.
Recently, a glycoprotein of 120 kDa named SHPS-1 was identi®ed as a substrate of v-Src (Fujioka et al., 1996) . SHPS-1 appears to be identical to SIRPa1 (Kharitonenkov et al., 1997) , BIT (Sano et al., 1997) or P84 (Comu et al., 1997) . SHPS-1 is a receptor-like protein associated with protein tyrosine phosphatases with two SH2 domains, SHP-1 and SHP-2. SHPS-1 has three immunoglobulin-like domains in its extracellular region and four YXX(L/V/I) motifs, tyrosine phosphorylation sites of which Tyr449 and Tyr473 are critical for SHP-2 binding, in its cytoplasmic region (Takada et al., 1998) . Various mitogens such as epidermal growth factor (EGF), insulin and platelet derived growth factor (PDGF) induced tyrosine phosphorylation of SHPS-1 and its association with SHP-2. Takada et al. (1998) reported that overexpression of wild-type SHPS-1 signi®cantly increased mitogen-activated protein kinase (MAP kinase) activity in response to insulin, while overexpression of mutant SHPS-1 lacking SHP-2-binding sites markedly inhibited the MAP kinase activation. In contrast, Kharitonenkov et al. (1997) reported that overexpression of SIRPa1, a human homologue of SHPS-1, inhibited the activation of MAP kinase by insulin or EGF and the cell transformation by v-fms. Thus SHPS-1 may play an important role in cell proliferation, but whether it has positive role or negative one remains to be clari®ed.
To obtain more clues, we examined its role in cells expressing various src mutants. It was somewhat unexpected to ®nd that transformation by v-src virtually suppressed the expression of SHPS-1. In this report, we show evidence that the suppression of SHPS-1 expression correlates with the transforming activity of v-Src and the Ras-MAP kinase signaling is critical for the suppression. In addition, overexpression of SHPS-1 in v-src-transformed 3Y1 suppresses anchorage independent growth of the cells.
Results

Expression of SHPS-1 in 3Y1 and SR3Y1
We ®rst prepared antibodies against SHPS-1 by use of GST fusion proteins. Four dierent types of SHPS-1 cDNA fragments ( Figure 1a) were cloned by RT ± PCR as described in Materials and methods. Anity puri®ed rabbit antibodies against these GST-SHPS-1 proteins recognized same size glycoprotein of 120 kDa compatible with SHPS-1 in 3Y1 lysates by immunoblotting ( Figure 1b) .
We next examined SHPS-1 phosphorylation in SR3Y1, 3Y1 transformed with subgroup A type of Schmidt-Ruppin strain of RSV. It was somewhat unexpected, however, that our antibodies detected only a trace of SHPS-1 protein in SR3Y1 compared to that of 3Y1 (Figure 1c ). To exclude the inhibitory eect of tyrosine phosphorylation of SHPS-1 on antibody binding, tyrosine phosphorylated glycoproteins puri®ed from SR3Y1 by WGA agarose (Hamaguchi et al., 1990) was dephosphorylated by potato acid phosphatase (PAP) and, subsequently, immunoblotted with anti-SHPS-1 antibodies. As shown in Figure 1d , PAP treatment did not enhance SHPS-1 detection by the antibody raised against type-c GST-SHPS-1 in SR3Y1, although tyrosine phosphorylated glycoprotein of 130 kDa (Hamaguchi et al., 1990) was dephosphorylated. These results strongly suggest that steady state level of SHPS-1 protein is extremely decreased in SR3Y1. Since all antibodies we prepared showed similar results (data not shown), we used type-c antibody (Figure 1a,b) in the following experiments.
Expression of SHPS-1 in various cell lines
To examine whether the suppression of SHPS-1 expression is speci®c for SR3Y1, SHPS-1 levels in Rat-1, Balb3T3 and Rat primary ®broblasts transformed with v-src were examined (Figure 2 ). While SHPS-1 expression was maintained to the level comparable to 3Y1 in the parental cells, all these cells transformed with v-src showed drastic reduction of SHPS-1 expression.
SHPS-1 mRNA levels and half-life of its product in 3Y1 and SR3Y1
We next examined whether down-regulation of SHPS-1 was controlled at the transcriptional level or the protein-level. SHPS-1 mRNA levels in 3Y1 and SR3Y1 were examined by the Northern blot analysis and by the quantitative RT ± PCR analysis. As shown in Figure 3a ,b, steady state levels of SHPS-1 mRNA in SR3Y1 were dramatically decreased compared with those in 3Y1, suggesting that SHPS-1 expression in SR3Y1 is controlled at the transcriptional level.
To exclude the possibility that tyrosine phosphorylation of SHPS-1 might facilitate its degradation, we assayed the half-lives of SHPS-1 protein in ts3Y1, 3Y1 transformed with a temperature sensitive mutant of RSV, NY72-4 (Figure 4 ). In ts3Y1, expression of SHPS-1 was down-regulated in a transformation speci®c manner. While a large amount of SHPS-1 protein was detectable to the level similar to normal 3Y1 at the nonpermissive temperature (39.58C), only a trace of SHPS-1 was detectable at the permissive temperature (348C). ts3Y1 cells were pulse labeled with 35 S-methionine and chased for the indicated times, and SHPS-1 protein was immunoprecipitated with anti-SHPS-1. When cells were incubated at the permissive temperature, only a trace of SHPS-1 protein was detected, while large amounts of SHPS-1 was found at the nonpermissive temperature (Figure 4b) . In both conditions, however, SHPS-1 proteins had similar lengths of half-life of approximately 8 h. We next labeled cells incubated at the nonpermissive temperature and subsequently chased them at the permissive or the nonpermissive temperatures ( Figure 4c ). In both temperatures, SHPS-1 again showed similar lengths of half-life.
Expression of SHPS-1 in cells transfected with src mutants
To con®rm that suppression of SHPS-1 expression is transformation-speci®c, we examined its expression in cells expressing various types of src. Wild-type c-src and mutant forms of v-src were ligated into pBabe vector and transfected into 3Y1. Drug-resistant colonies were selected. c-Src3Y1 overexpresses wild-type c-src which is inactive in transformation (Figure 5b ). vSH3c-Src3Y1 is a chimeric construct of mutant c-src, which has v-src sequence substitution in SH3 domain, and active in protein kinase (Miyazaki et al., 1999) and cell transformation ( Figure 5b ). G2A3Y1 and G2E3Y1 express mutant v-Src kinases in which Gln at position 2 of v-Src was substituted to Ala and Glu by PCR, respectively. These nonmyristoylated forms of v-Src are active in protein kinase but lack transforming activity (Kamps et al., 1985) (Figure 5b ). As shown in Figure 5c , SHPS-1 expression was somewhat lower but still maintained in c-Src3Y1. In contrast, its expression was strongly suppressed in vSH3c-Src3Y1 to the level similar to SR3Y1. On the other hand, SHPS-1 expression was maintained in G2A3Y1 and G2E3Y1 to the levels similar to 3Y1. In contrast to SHPS-1, SHP-2 was expressed to the similar levels both in transformed and nontransformed cells (Figure 5c ). To exclude the possibility that clonal dierence of cells might aect SHPS-1 levels, we examined several independent clones transfected with wild-type v-src, G2E v-src or G2A v-src. As Figure 5c , all v-srctransfected clones showed suppression of SHPS-1 expression, while all clones of G2A and G2E v-srctransfected cell did not.
Tyrosine phosphorylation of SHPS-1 and membranebinding of SHP-2 in SR3Y1
We examined tyrosine phosphorylation of SHPS-1 and its complex formation with SHP-2 in 3Y1, c-Src3Y1, vSH3c-Src3Y1, G2A3Y1 and SR3Y1. SHPS-1 protein was immunoprecipitated and probed with anti-phosphotyrosine, anti-SHPS-1 or anti-SHP-2 antibodies (Figure 6a ). In c-Src3Y1 and G2A3Y1, SHPS-1 was readily phosphorylated and their levels were higher than that of parental 3Y1. In contrast, only a trace of SHPS-1 was detectable in SR3Y1 and its net phosphorylated form was small. When relative amounts of SHPS-1 protein were normalized to compare their phosphorylation-levels, c-Src3Y1, vSH3c-Src3Y1 and SR3Y1 had 3.4-, 3.5-and 3.5-fold higher phosphorylation-levels than that in 3Y1, respectively. On the other hand, phosphorylation level of SHPS-1 in G2A3Y1 was 1.3-fold higher than that in 3Y1. Consonant with SHPS-1 phosphorylation, anti-SHPS-1 immunoprecipitates from G2A3Y1 and 3Y1 had larger amounts of SHP-2, whereas those from vSH3c-Src3Y1 and SR3Y1 contained trace levels of SHP-2 (Figure 6a ).
Since the role of SHPS-1 was supposed to recruit cytosolic SHP-2 to the plasma membrane (Fujioka et al., 1996; Stein-Gerlach et al., 1998) , SHP-2 might change its localization in SR3Y1. We, therefore, examined the subcellular localization of SHP-2 and SHPS-1 in 3Y1 and SR3Y1. 3Y1 and SR3Y1 were fractionated into S100 (cytosol) and P100 (crude membrane) fractions by hypotonic disruption followed by dierential centrifugation (Figure 6b ). P100 fractions were further fractionated into soluble and insoluble fractions by treatment with 1% Triton X-100 followed by centrifugation as described previously (Hamaguchi and Hanafusa, 1989) . SHPS-1, SHP-2 and v-Src proteins in each fraction were examined by immunoblotting with speci®c antibodies. In 3Y1, SHP-2 predominantly localized in the cytosolic fraction, and around 10% of SHP-2 was found in the membrane fraction. In contrast, SR3Y1 had a larger amount of membrane-bound SHP-2, although its SHPS-1 expression was dramatically suppressed. Approximately half of SHP-2 was found as a membrane-bound form in SR3Y1, one-third of which was resistant to Triton X-100 extraction.
We reported previously that most of the tyrosine phosphorylated cellular proteins were associated with plasma membrane in SR3Y1 (Hamaguchi and Hanafusa, 1989) . Thus, in the absence of SHPS-1, the membrane-bound SHP-2 may form a complex with other tyrosine phosphorylated proteins by its SH2 domain. We examined tyrosine phosphorylated proteins associated with SHP-2. The crude membrane fractions were immunoprecipitated with anti-SHP-2 Figure 6c , multiple tyrosine phosphorylated proteins were coprecipitated with SHP-2 in SR3Y1, while only 110 ± 120 kDa peptides, of which 110 kDa may be SHPS-1, coprecipitated in 3Y1. When anti-SHP-2 immunoprecipitates were probed with anti-SHPS-1, immunoprecipitate from 3Y1 contained substantial amounts of SHPS-1 (Figure 6d ). In contrast, SHPS-1 was undetectable in the anti-SHP-2 immunoprecipitate from SR3Y1. We also examined p130Cas, vinculin, FAK, Pyk2, IRS-1, PDGF receptor, p120, paxillin, cortactin, PI3 kinase (p85), Sam68, CSK and c-Crk in the immunoprecipitates, but none of them was detected coprecipitation with SHP-2 (data not shown). However, we found that one of the major tyrosine phosphorylated proteins coprecipitated with SHP-2 was v-Src itself (Figure 6d ). We also found coprecipitation of b-catenin with SHP-2.
Ras-MEK-MAPK pathway is required for the suppression of SHPS-1
To investigate the signaling critical for the suppression of SHPS-1, eect of herbimycin A, a potent inhibitor of tyrosine kinase (Hamaguchi et al., 1993b) , was examined. SR3Y1 cells treated with herbimycin A showed increase of SHPS-1 expression up to 7.6-fold higher than that in untreated cells (Figure 7a) .
We next examined the role of Ras by use of dominant negative ras. S17N ras, a mutant ras with Asn substitution for Ser at postion 17 of Ras H , which was shown to yield a dominant inhibitory eect on endogenous Ras (Feig and Cooper, 1988) . We established a SR3Y1 cell line (N17RasSR3Y1) in which S17N ras is conditionally expressed under the control of mouse mammary tumor virus promoter/ enhancer (Thant et al., 1997). When S17N Ras was Figure 6 Tyrosine phosphorylation of SHPS-1 and localization of SHP-2. (a) Cell lysates from 3Y1, c-Src3Y1, vSH3c-Src3Y1, SR3Y1, G2A3Y1 are immunoprecipitated with anti-SHPS-1. Immunoprecipitates were probed with anti-phosphotyrosine (upper panel), anti-SHPS-1 (middle panel) or anti-SHP-2 (lower panel). (b) 3Y1 and SR3Y1 were fractionated into S100 and P100 fractions. P100 fractions were further fractionated into soluble and insoluble fractions. SHPS-1, SHP-2 and Src proteins in each fraction were probed with speci®c antibodies. (c) P100 fractions from 3Y1 and SR3Y1 were immunoprecipitated with anti-SHP-2. P100 lysates (lanes 1, 2) and immunoprecipitates (lanes 3, 4) were subjected to SDS ± PAGE followed by immunoblotting with antiphosphotyrosine. (d) The membrane was reprobed with anti-SHPS-1 (upper panel), anti b-catenin (second panel), anti-SHP-2 (third panel) or anti-Src (lower panel) expressed in the cell line by treatment with dexamethasone, SHPS-1 expression increased up to threefold higher than untreated N17RasSR3Y1 and ninefold higher than parental SR3Y1 (Figure 7a) .
To obtain more clues, we investigated the critical signaling for the suppression of SHPS-1 expression by use of other oncogenes. 3Y1 cells transformed with Fujinami sarcoma virus (FSV3Y1) or active Mek (Mek3Y1) were prepared (Figure 7b ), and SHPS-1 expression in these cells was examined. Mek EE is a constitutively activated form of Mek1 with substitutions from Ser to Glu at position 218 and 222 (Gotoh et al., 1994) . Myc-epitope tagged Mek EE was made by PCR, ligated into pBabe vector and transfected. Drug resistant colonies were selected and Mek EE expression was monitored by immunoblotting with anti-Myc (Kurata et al., 2000) . As shown in Figure 7c , MAP kinase was constitutively activated by the expression of Mek EE in Mek3Y1. We found that expression of SHPS-1 protein was strongly suppressed both in FSV3Y1 and Mek3Y1 to the levels similar to SR3Y1 (Figure 7c ). By the RT ± PCR assay, suppression of SHPS-1 expression in these cells was con®rmed to be transcriptional level ( Figure  7d ). These results strongly suggest that constitutive activation of the Ras-MAP kinase signaling is required for the suppression of SHPS-1 expression.
Expression of SHPS-1 suppresses anchorage independent growth of SR3Y1
To investigate the function of SHPS-1 in cell transformation, we generated stable transfectants of SR3Y1 expressing SHPS-1. SHPS-1 was ligated into either pBabe-puro vector or pMx-puro retrovirus vector and introduced into SR3Y1 by LIPOFECTA-MIN-mediated transfection or virus infection and drug-resistant cells were selected. Several independent colonies that express large amounts of SHPS-1 were isolated. Since all of these clones showed basically similar results (data not shown), results with representative two clones with dierent vectors were shown in Figure 8 . Expression of SHPS-1 perturbed neither the expression of SHP-2 nor that of v-Src (Figure 8a ). SR3Y1 expressing SHPS-1 did not show any growth retardation compared with SR3Y1 (data not shown). Cell morphology of SR3Y1 expressing SHPS-1 was slightly¯attened but remained rounded up (Figure 8c) . Interestingly, overall pro®le of tyrosine phosphorylation of cellular proteins was not grossly suppressed nor perturbed by SHPS-1 expression (Figure 8b ). We found, however, clear eect of exogenous SHPS-1 expression on the anchorage-independent growth of SR3Y1. SR3Y1 clones which expressed higher levels of SHPS-1 were suspended in soft agar to allow anchorage independent growth. Figure 8d shows the result obtained with one of the representative clones used for the above experiments, but similar results were obtained with several independent clones (graph in Figure 8d ). While average diameter of the SR3Y1 colonies infected with control virus was around 180 mm after 10 day-incubation, that of SHPS-1-overexpressing SR3Y1 was around 40 mm. These results strongly suggest that exogenous expression of SHPS-1 in SR3Y1 led to a drastic suppression of anchorage independent growth of the cells.
Discussion
In this study, we showed, for the ®rst time, that cell transformation by v-src substantially suppressed the SHPS-1 expression, and this suppression closely associated with transforming activity of src. In addition, overexpression of SHPS-1 in v-src-transformed cells led to the suppression of the anchorage independent growth of the cells. These results clearly demonstrated that suppression of SHPS-1 expression is a pivotal event for cell transformation by v-Src. In addition, suppression of SHPS-1 was observed not only in SR3Y1 and vSH3c-Src3Y1 but also in FSV3Y1 and Mek3Y1, suggesting that the suppression of SHPS-1 expression is not restricted to v-src but associated with other oncogenes.
We found that treatment of cells with herbimycin A and the expression of S17N ras restored SHPS-1 expression in SR3Y1, whereas cell transformation by active Mek suppressed SHPS-1 expression. These results suggest that constitutive activation Ras-MAP kinase cascade is required for the suppression of SHPS-1 expression. In contrast, rapamycin, an inhibitor of Akt kinase which is a down-stream eector of phosphatidylinositol-3 kinase, or phorbol 12-myristate 13-acetate which can down regulate protein kinase C (PKC) showed no eects on SHPS-1 expression in SR3Y1 (data not shown). It is likely that Akt kinase and PKC are not critical for the suppression of SHPS-1 expression.
We found that the half-life of SHPS-1 protein was not decreased but its mRNA expression was virtually suppressed in SR3Y1. These results suggest that downregulation of SHPS-1 expression by RAS-MAP kinase pathway is at the transcriptional level. However, it is unclear yet whether AP-1 dependent transcription is involved in the suppression and whether Ras-MAP kinase-AP-1 directly controls the suppression. An extensive study including identi®cation of the silencer would be required.
By its feature to be phosphorylated at the immunoreceptor tyrosine-based inhibitory motif (ITIM) and bound with SHP-1 or SHP-2, SHPS-1 was thought to function as a docking protein for these SH2-containing PTPases in response to cell growth stimulation (Fujioka et al., 1996) . SHP-2 is proposed as a positive mediator of cell growth and its recruitment to the plasma membrane upon growth stimulation has been observed (Stein-Gerlach et al., 1998) . Takada et al. (1998) reported that overexpression of SHPS-1 enhanced insulin-induced activation of MAP kinase, and mutation in tyrosine residues, Tyr449 and Tyr473, abolished the tyrosine phosphorylation of SHPS-1, its association with SHP-2 and activation of MAP kinase. In this study, however, we showed evidence that tyrosine phosphorylation of SHPS-1 was elevated in c-Src3Y1, G2E3Y1 and G2A3Y1, all of which are not transformed, while net amount of tyrosine phosphorylated SHPS-1 was substantially decreased in SR3Y1 (Figure 6a ). In addition, the amount of SHP-2 bound to SHPS-1 was also decreased in SR3Y1 (Figure 6a,d) . These results suggest that tyrosine phosphorylation of SHPS-1 and its complex formation with SHP-2, which might be necessary for normal cell proliferation, may not be critical for the oncogenic growth of SR3Y1. We found that, in SR3Y1, the major fraction of SHP-2 was found in the crude membrane fraction, although SHPS-1 expression was substantially suppressed (Figure 6b) . In addition, SHP-2 in the crude membrane fraction formed a complex with multiple tyrosine phosphorylated proteins that included v-Src but lacked detectable amounts of SHPS-1, suggesting that, in SR3Y1, SHP-2 has multiple binding partners to be recruited to the plasma membrane.
Type II tumor suppression is proposed to be transcriptionally down-regulated in speci®c tumor cell lines, in contrast to type I tumor suppressor genes such as p53 and Rb which are mutated or deleted in tumor cells (Lee et al., 1991) . Candidate type II tumor suppressor genes such as NO3 (Ozaki and Sakiyama, 1994) , maspin (Zou et al., 1994) , ela®n (Zhang et al., 1995) , a-actinin (Gluck et al., 1993) , tropomyosin 1 and 2 (Prasad et al., 1993; Gimona et al., 1996) and SSeCKS (Lin and Gelman, 1997) have been isolated. Although none of their anti-tumor functions has been clari®ed yet, their de®nition as tumor suppressors is strengthened by at least two criteria (Lin and Gelman, 1997) . Firstly, demonstration of down-regulated expression in tumor cells. Secondly, demonstration of tumor-suppressive activity when ectopically reexpressed in tumor cell lines. As we showed in this study, cell transformation by v-src substantially suppressed the SHPS-1 expression, while reexpression of SHPS-1 in SR3Y1 led to the suppression of the anchorage independent growth of the cells. These results suggest that SHPS-1 may be a candidate of type II tumor suppressor. Interestingly, overall pro®le of cellular protein phosphorylation was not suppressed nor perturbed by SHPS-1 reexpression, suggesting that expression of SHPS-1 in SR3Y1 does not simply inhibit Src kinase nor activate massive dephosphorylation. We also found that exogenous expression of SHPS-1 did not grossly inhibit the growth of SR3Y1 when cultured on the plates with the liquid medium, suggesting that exogenous SHPS-1 does not have a toxic eect on cell proliferation. Identi®cation of downstream signaling of SHPS-1 critical for the suppression of anchorage independent growth is an important problem to be clari®ed.
Materials and methods
Cell and antibodies
3Y1, SR3Y1, TsNY72 3Y1, Rat-1 and Balb3T3 cells were cultured as described previously (Hamaguchi and Hanafusa, 1987) . Anti-SHP-2, peroxidase-labeled anti-phosphotyrosine (PY20H) (Transduction Laboratories), Anti-Src (Mo327), anti-ERK2 (Santa Cruz Biotechnology), anti-phospho-MAP kinase (New England Biolabs), anti myc antibodies (Bahco Berkzley) were purchased.
To generate the polyclonal antibody against rat SHPS-1, four dierent types of cDNA fragments for SHPS-1 were cloned by RT ± PCR from 3Y1 with the SuperScript Preampli®cation System (Gibco-BRL). The primer paired used for the RT ± PCR; 5'-cacggatccacgagcccgagaagaatgc-3' and 5'-gccgaattcacttcctctggacttggac-3', 5'-cacggatccacgagcccgagaagaatgc-3' and 5'-gaggaattcctctggcctaggcagttt-3', 5'-ccaggatcctaacccagatccaggaca-3' and 5'-gccgaattcacttcctctggacttggac-3' or 5'-ccaggatcctaacccagatccaggaca-3' and 5'-gaggaattcctctggcctaggcagttt-3'. The resulting fragments were subcloned into pGEX-5X1 (Pharmacia). The GST fusion proteins were used for immunization. Rabbit sera were puri®ed by anity chromatography.
Construction of plasmids and transfection
The mutant src genes were prepared by the modi®ed overlap extension method as previously described . Generated PCR products were ligated into pBabe-puro expression vector and their sequences were con®rmed. Murine MEK1 and its constitutive active form, MEK1 EE , were prepared by PCR as described (Kurata et al., 2000) . Various src mutants and MEK genes ligated with the pBabepuro were transfected into 3Y1 with Lipofectamine (Life Technologies, Inc.) as described (Thant et al., 1997) .
For the expression of SHPS-1 gene, pBabe-puro vector or a retrovirus vector, pMx-puro (Kitamura et al., 1995) , was employed. In case of pMx-puro, recombinant retroviruses were recovered from Bosc23 cells transfected with SHPS-1 gene and infected to SR3Y1 as described (Kitamura et al., 1995) . A recombinant virus made by vector only was used as a control.
Northern blot and RT ± PCR mRNA samples were puri®ed, subjected to electrophoresis transferred to Hybond N + membrane (Amersham Life Science). SHPS-1 cDNA probe labeled with alkaline phosphatase by the AlkPhos-Direct Kit (Amersham Pharmacia Biotech) was hybridized, washed and exposed to the ®lm.
For the quantitative RT ± PCR, mRNA was isolated by GlassMAX RNA Microisolation Spin Cartridge System (Gibco-BRL). cDNA synthesis was performed with Superscript preampli®cation system (Gibco-BRL). SHPS-1 cDNAs were ampli®ed by PCR for 20 or 25 cycles with sense primer (5'-CACGGATCCACGAGCCCGAGAAGAATGC) and antisense primer (5'-GCCGAATTCACTTCCTCTGGACT-TGGAC). As an internal control, rat b-actin cDNA was also ampli®ed (Shibata et al., 1998) .
Potato acid phosphatase treatment
PAP treatment was performed as described (Cooper and King, 1986) . Brie¯y, glycoprotein fractions puri®ed with WGA agarose from cells were incubated in 50 mM PIPES (pH 6.0), 1 mM dithiothreitol, 20 mM leupepsin containing 2 mg of potato acid phosphatase (Sigma) for 10 min at 308C.
Uptake of GTP onto Ras
Uptake of GTP onto Ras were determined as described (Thant et al., 1999) .
